Don't throw out the baby with the bathwater: On optimizing cure and reducing toxicity in Hodgkin's lymphoma

Journal of Clinical Oncology

Volumn 24, Issue 4, 2006, Pages 544-548

  Yahalom, Joachim ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CHLORMETHINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GEMCITABINE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE; ANTINEOPLASTIC AGENT;

CANCER CHEMOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; EDITORIAL; HODGKIN DISEASE; HUMAN; ISCHEMIC HEART DISEASE; LEUKEMIA; LUNG CANCER; LUNG TOXICITY; MEDICAL PRACTICE; MULTIPLE CYCLE TREATMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; CORONARY ARTERY DISEASE; LYMPH NODE; NOTE; PATHOLOGY; RADIATION EXPOSURE; RADIATION INJURY; SURVIVAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CORONARY DISEASE; HODGKIN DISEASE; HUMANS; LYMPH NODES; NEOPLASMS, RADIATION-INDUCED; RADIOTHERAPY DOSAGE; RADIOTHERAPY, ADJUVANT; RANDOMIZED CONTROLLED TRIALS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 33644840910     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.04.4396     Document Type: Editorial

References (39)

1. Spanier M: Thomas Murner's Narrenbeschworung. Halle, Germany, VEB Max Niemeyer, 1967
2. DeVita VT Jr: Hodgkin's disease: Clinical trials and travails. N Engl J Med 348:2375-2376, 2003
3. Longo DL: Radiation therapy in the treatment of Hodgkin's disease: Do you see what I see? J Natl Cancer Inst 95:928-929, 2003
4. Longo DL: Hodgkin disease: The sword of Damocles resheathed. Blood 104:3418, 2004
5. Longo DL: Radiation therapy in Hodgkin disease: Why risk a Pyrrhic victory? J Natl Cancer Inst 97:1394-1395, 2005
6. Canellos GP: Chemotherapy alone for early Hodgkin's lymphoma: An emerging option. J Clin Oncol 23:4574-4576, 2005
7. Koontz B, Kirkpatrick J, Clough R, et al: Combined modality therapy versus radiotherapy alone for treatment of early stage Hodgkin disease: Cure versus complications. J Clin Oncol 24:605-611, 2006
8. NCCN guidelines for Hodgkin's Disease/Lymphoma, version 1.2006. http://www.nccn.org/professionals/physician_gls/PDF/hodgkins.pdf
9. Kaplan H: The radical radiotherapy of Hodgkin's disease. Radiology 78:553-561, 1962
10. DeVita V, Serpick A, Carbone P: Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Intern Med 73:881-895, 1970
11. Travis LB, Gospodarowicz M, Curtis RE, et al: Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. J Natl Cancer Inst 94:182-192, 2002
12. van Leeuwen FE, Klokman WJ, Stovall M, et al: Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease. J Natl Cancer Inst 95:971-980, 2003
13. Ng AK, Bernardo MP, Weller E, et al: Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger. J Clin Oncol 20:2101-2108, 2002
14. Canellos GP, Anderson JR, Propert KJ, et al: Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327:1478-1484, 1992
15. Press OW, LeBlanc M, Lichter AS, et al: Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease. J Clin Oncol 19:4238-4244, 2001
16. Bonadonna G, Bonfante V, Viviani S, et al: ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: Long-term results. J Clin Oncol 22:2835-2841, 2004
17. Loeffler M, Diehl V, Pfreundschuh M, et al: Dose-response relationship of complementary radiotherapy following four cycles of combination chemotherapy in intermediate-stage Hodgkin's disease. J Clin Oncol 15:2275-2287, 1997
18. Diehl V, Brillant C, Engert A, et al: HD10: Investigating reduction of combined modality treatment intensity in early stage Hodgkin's lymphoma. Interim analysis of a randomized trial of the German Hodgkin Study Group (GHSG). J Clin Oncol 23: 561s, 2005 (supp 1; abstr 6506)
19. Engert A, Schiller P, Josting A, et al: Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: Results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 21:3601-3608, 2003
20. Ferme C, Eghbali H, Hagenbeek A, et al: MOPP/ABV hybrid and irradiation in unfavorable supradiaphragmatic clinical stages I-II Hodgkin's disease: Comparison of three treatment modalities. Preliminary results of the EORTC-GELA H8-U randomized trial in 995 patients. Blood 96:A576, 2000
21. Eghbali H, Brice P, Creemers G-Y, et al: Comparison of three radiation dose levels after EBVP regimen in favorable supradiaphragmatic clinical stages (CS) I-II Hodgkin's Lymphoma (HL): Preliminary results of the EORTC-GELA H9-F trial. Blood 106:240a, 2005 (abstr 814)
22. Laskar S, Gupta T, Vimal S, et al: Consolidation radiation after complete remission in Hodgkin's disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: Is there a need? J Clin Oncol 22:62-68, 2004
23. Meyer RM, Gospodarowicz MK, Connors JM, et al: Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol 23:4634-4642, 2005
24. Straus DJ, Portlock CS, Qin J, et al: Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood 104:3483-3489, 2004
25. Nachman JB, Sposto R, Herzog P, et al: Randomized comparison of lowdose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy. J Clin Oncol 20:3765-3771, 2002
26. Aleman BM, Raemaekers JM, Tirelli U, et al: Involved-field radiotherapy for advanced Hodgkin's lymphoma. N Engl J Med 348:2396-2406, 2003
27. Duggan DB, Petroni GR, Johnson JL, et al: Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: Report of an intergroup trial. J Clin Oncol 21:607-614, 2003
28. Yahalom J, Mauch P: The involved field is back: Issues in delineating the radiation field in Hodgkin's disease. Ann Oncol 13:79-83, 2002 (suppl 1)
29. Yahalom J: Breast cancer after Hodgkin disease: Hope for a safer cure. JAMA 290:529-531, 2003
30. Goodman KA, Toner S, Hunt M, et al: Intensity modulated radiation therapy in the treatment of lymphoma involving the mediastinum. Int J Radiat Oncol Biol Phys 62:198-206, 2005
31. Girinsky T, Pichenot C, Beaudre A, et al: Is intensity-modulated radiotherapy better than conventional radiation treatment and three-dimensional conformal radiotherapy for mediastinal masses in patients with Hodgkin's disease, and is there a role for beam orientation optimization and dose constraints assigned to virtual volumes? Int J Radiat Oncol Biol Phys 64:218-226, 2005
32. Travis LB, Hill DA, Dores GM, et al: Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA 290:465-475, 2003
33. Kuttesch JF Jr, Wexler LH, Marcus RB, et al: Second malignancies after Ewing's sarcoma: Radiation dose-dependency of secondary sarcomas. J Clin Oncol 14:2818-2825, 1996
34. Lorigan P, Radford J, Howell A, et al: Lung cancer after treatment for Hodgkin's lymphoma: A systematic review. Lancet Oncol 6:773-779, 2005
35. Josting A, Wiedenmann S, Franklin J, et al: Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: A report from the German Hodgkin's Lymphoma Study Group. J Clin Oncol 21:3440-3446, 2003
36. Salloum E, Doha R, Schubert W, et al: Second solid tumors in patients with Hodgkin's disease cured after radiation or chemotherapy plus adjuvant low-dose radiation. J Clin Oncol 14:2435-2443, 1996
37. Friedberg JW, Neuberg D, Kim H, et al: Gemcitabine added to doxorubicin, bleomycin, and vinblastine for the treatment of de novo Hodgkin disease: Unacceptable acute pulmonary toxicity. Cancer 98:978-982, 2003
38. Bredenfeld H, Franklin J, Nogova L, et al: Severe pulmonary toxicity in patients with advanced-stage Hodgkin's disease treated with a modified bleomycin, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone, and gemcitabine (BEACOPP) regimen is probably related to the combination of gemcitabine and bleomycin: A report of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 22:2424-2429, 2004
39. Martin WG, Ristow KM, Habermann TM, et al: Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma. J Clin Oncol 23:7614-7620, 2005 zlj-044396.xml